Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

With Strong Q3 Financials, Pfizer Says It's Ready For Generic Competition To Lipitor

This article was originally published in The Pink Sheet Daily

Executive Summary

The world's largest pharma highlights sales growth of Prevnar 13, Enbrel and Lyrica, emerging markets growth, and a developing plan to sell off animal health and nutritional units.

You may also be interested in...



Can Watson Give Birth To A Pregnancy Franchise As It Helps Lay Lipitor To Rest?

Watson is progressing on a multi-year effort to diversify beyond its core U.S. generics business into branded drugs and international markets.

Countdown To Generic Lipitor: Watson Expects Pfizer To Retain 40% Market Share For Six Months

Watson, which will launch an authorized generic Nov. 30, says Pfizer is trying to get pharmacy benefit managers to give Lipitor preferred formulary status.

Countdown To Generic Lipitor: Watson Expects Pfizer To Retain 40% Market Share For Six Months

Watson, which will launch an authorized generic Nov. 30, says Pfizer is trying to get pharmacy benefit managers to give Lipitor preferred formulary status.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS072998

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel